Skip to main content
An official website of the United States government
Program Official
Principal Investigator
Patricia Ann Thompson
Awardee Organization

University Of Arizona
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

University of Arizona Cancer Prevention Clinical Trials Network

The University of Arizona Cancer Prevention Clinical Trials Network (UA CP-CTNet) is at the forefront of advancing cancer prevention through early-phase clinical trials, with a focus on five major organ systems: skin, gastrointestinal, lung and upper aerodigestive, breast and gynecologic, and prostate and other urologic cancers. With strong scientific and academic leadership from Lead Academic Organization (LAO) at the University of Arizona has partnered with George Washington University and 20+ highly collaborative nationally recognized Affiliate Organizations (AOs), UA CP-CTNet rigorously evaluates preventive agents designed to prevent or intercept cancer at its earliest stages. High-impact studies led by the network have contributed to HPV vaccine guidelines, evaluated the preventive potential of low-dose apalutamide in prostate cancer, and are targeting at risk patients such as organ transplant recipient, populations including smokers, and community groups including firefighters. Additionally, UA CP-CTNet is exploring innovative strategies, such as topical immune modulators and microbiome-modifying agents, to prevent skin and cervical cancers. The four core objectives of UA CPCTNet are: (1) to execute scientifically rigorous early-phase trials that target key molecular pathways involved in cancer prevention across these five organ systems, ensuring trials are aligned with the most current scientific advancements; (2) to characterize the clinical activity and biological effects of preventive agents, focusing on molecular targets, immune responses, and key carcinogenesis markers to assess their potential efficacy and safety; (3) to enhance trial efficiency and inclusivity by leveraging modern statistical and trial design methods and by employing a multipronged process involving stakeholder and investigators to consider eligibility and participation barriers and recruitment strategies toward optimizing access and inclusion; and (4) to formalize the UA CP-CTNet training and professional development pipeline to foster the growth of future leaders in cancer chemoprevention. Through these objectives, UA CP-CTNet aims to generate critical early phase clinical and biomarker guided efficacy and safety evidence on promising prevention agents that will drive forward cancer prevention efforts, influence public health policies, and ensure that future cancer prevention research continues to benefit diverse populations and at-risk groups.

Publications

  • Centuori SM, Caulin C, Bauman JE. Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention. Current treatment options in oncology. 2021 May 15;22(6):52. PMID: 33991232
  • Borden ES, Adams AC, Buetow KH, Wilson MA, Bauman JE, Curiel-Lewandrowski C, Chow HS, LaFleur BJ, Hastings KT. Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma. Cancers. 2021 Dec 21;14. (1). PMID: 35008167
  • Julian R, Savani M, Bauman JE. Immunotherapy Approaches in HPV-Associated Head and Neck Cancer. Cancers. 2021 Nov 23;13. (23). PMID: 34884999
  • Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nature reviews. Disease primers. 2020 Nov 26;6(1):92. PMID: 33243986
  • Luna AJ, Sterk RT, Griego-Fisher AM, Chung JY, Berggren KL, Bondu V, Barraza-Flores P, Cowan AT, Gan GN, Yilmaz E, Cho H, Kim JH, Hewitt SM, Bauman JE, Ozbun MA. MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors. PLoS pathogens. 2021 Jan 22;17(1):e1009216. doi: 10.1371/journal.ppat.1009216. eCollection 2021 Jan. PMID: 33481911
  • Samimi G, House M, Benante K, Bengtson L, Budd T, Dermody B, DeShong K, Dyer V, Kimler BF, Sahasrabuddhe VV, Siminski S, Ford LG, Vilar E, Szabo E. Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs. Cancer prevention research (Philadelphia, Pa.). 2022 May 3;15(5):279-284. PMID: 35502553
  • Geiger JL, Cedars ED, Zang Y, Normolle DP, Li H, Grandis JR, Centuori S, Johnson DE, Bauman JE. Clinical trials optimizing investigator and self-collection of buccal cells for RNA yield. Laryngoscope investigative otolaryngology. 2021 Jan 18;6(1):116-121. doi: 10.1002/lio2.516. eCollection 2021 Feb. PMID: 33614939
  • Centuori SM, Bhattacharya D. Locally produced autoantibodies in cancer. Cell. 2022 Mar 31;185(7):1110-1111. PMID: 35364029

Clinical Trials

Study Name Clinical Trial ID
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland NCT04530552
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers NCT05121051
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia NCT05237960
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome NCT05419011
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial NCT06184750
Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients NCT05699603
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters NCT06009926
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis NCT06557733